SULLA
LOE ApproachingNDAORALTABLET
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULLA is an oral tablet small-molecule drug approved by Bayer in 1966. The mechanism of action, pharmacologic class, and specific indications are not publicly documented in available data. Patient population and therapeutic use cannot be determined without additional clinical or regulatory information.
LOE Approaching
LOE-approaching lifecycle suggests reduced team size and declining marketing investment; career trajectory on legacy products typically involves portfolio rationalization and cost management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest minimal hiring activity on SULLA. Working on a LOE-approaching legacy product offers limited career acceleration; roles focus on defending market share and managing transition to generic competition rather than innovation or growth.
Brand ManagerField Sales Representative
Worked on SULLA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.